Hormonal
Long-term use of GLP-1 receptor agonists (≥78 weeks) significantly increases the risk of deep vein thrombosis (DVT) compared to placebo or other anti-diabetic drugs.
If you are taking a GLP-1 medication (like Ozempic, Wegovy, or Victoza) for more than a year, be aware that your risk of deep vein thrombosis (DVT) is higher than if you were not taking it. This risk is most notable in people with existing cardiovascular disease. However, the absolute increase in risk is small. Discuss any history of blood clots with your doctor before starting or continuing long-term therapy.
GLP-1RAs were found to significantly increase the risk of DVT when used for longer duration (≥78 weeks) (OR, 2.32 [95% CI, 1.49–3.60])
Why this rating
Meta-analysis of 39 RCTs with 70,499 participants, moderate quality evidence due to potential underreporting of adverse events.
Source
Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Venous Thromboembolism: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Yiwen Liu et al. · Journal of the American Heart Association · 2025
DOI 10.1161/jaha.124.039446
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →